ArticleNature biotechnology2024
Discovery of sparse, reliable omic biomarkers with Stabl.
Article in Nature biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Applications and challenges of biomarker-based predictive models in proactive health management.Frontiers in public health · 2025Pooled it
- An Exploratory Stability Selection (ESS) framework for robust predictor discovery: An application to physical resilience in aging populations.Experimental gerontology · 2026Article
- Interpretable deep neural network identifies robust biomarkers for diseases with mechanistic insights from omics data.Briefings in bioinformatics · 2026Article
- Molecular bioindicators for assessing environmental impacts of emerging contaminants.Fundamental research · 2026Review
- Machine learning-driven cancer diagnostics with improved robustness and interpretability.Chemical science · 2026Review
- MarkerScout: A Disease-Agnostic Machine Learning Framework for Biomarker Prediction from Multi-Scale Mechanistic Models.bioRxiv : the preprint server for biology · 2026Article
- An LSEC-focused computational drug repurposing platform for liver fibrosis: Identification of vorinostat and other LSEC-protective candidates.bioRxiv : the preprint server for biology · 2026Article
- Dissecting non-small cell lung cancer (NSCLC) with blood proteomics-from surgical to immunotherapeutic responses.NPJ precision oncology · 2026Article
- Benchmarking computational methods for multi-omics biomarker discovery in cancer.Briefings in bioinformatics · 2026Article
- Toward trustworthy artificial intelligence in multi-omics: a review of reproducibility, stability, and interpretability.Briefings in bioinformatics · 2026Review
- Innovations in biomarker stratification for precision oncology.Clinical and experimental medicine · 2026Review
- Prognostic biomarker discovery in pancreatic cancer through hybrid ensemble feature selection and multi-omics data.BioData mining · 2026Article
- Decoding TNBC architecture.Nature cancer · 2026Article
- Castl: robust identification of spatially variable genes in spatial transcriptomics via an ensemble-based framework.Briefings in bioinformatics · 2026Article
- Preoperative lymphocyte signature predicts pancreatic fistula after pancreatoduodenectomy.Communications medicine · 2026Article
- Metabolic characterization of tumor-immune interactions by multiplexed immunofluorescence reveals spatial mechanisms of immunotherapy response in non-small cell lung carcinoma (NSCLC).Nature communications · 2026Article
- Identification of a plasma proteomic signature associated with sudden cardiac death risk in the UK biobank.Frontiers in cardiovascular medicine · 2026Article
- Beyond AUC: a clinician's guide to building and trusting prediction models in oncology-a narrative review.Frontiers in oncology · 2026Review
- Systemic immune dysregulation in hypertensive disorders of pregnancy persists years after delivery.Frontiers in immunology · 2026Article
- Automation and machine learning drive rapid optimization of isoprenol production in Pseudomonas putida.Nature communications · 2025Article
Corrections and comments
- Commented on by
- Update of
Authors and funding
28 authors at 10 institutions in 3 countries.
Funding
Abstract
Adoption of high-content omic technologies in clinical studies, coupled with computational methods, has yielded an abundance of candidate biomarkers. However, translating such findings into bona fide clinical biomarkers remains challenging. To facilitate this process, we introduce Stabl, a general machine learning method that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling. Evaluation of Stabl on synthetic datasets and five independent clinical studies demonstrates improved biomarker sparsity and reliability compared to commonly used sparsity-promoting regularization methods while maintaining predictive performance; it distills datasets containing 1,400-35,000 features down to 4-34 candidate biomarkers. Stabl extends to multi-omic integration tasks, enabling biological interpretation of complex predictive models, as it hones in on a shortlist of proteomic, metabolomic and cytometric events predicting labor onset, microbial biomarkers of pre-term birth and a pre-operative immune signature of post-surgical infections. Stabl is available at https://github.com/gregbellan/Stabl .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.